wellrank.ai
Veozah logo

Veozah

First cited by AI Jun 11, 2026
veozah.com

Surfaced organically in AI answers about menopause and women's health. Not yet profiled.

AI Visibility

Visibility trend

Menopause and women's health, daily share of AI answers mentioning Veozah, through Jun 13, 2026.

8.3%

Avg position when mentioned: 1.0

By engine

Where Veozah is strong, and where it is invisible.

  • Claude
    33.3%

Mention sentiment

Tone of AI mentions across all tracked answers.

  • 3 positive mentions
  • 0 neutral
  • 0 mixed or cautious

Recent AI answers mentioning Veozah

ClaudeJun 13, 2026, 11:06 UTC
What is the best non hormonal treatment for hot flashes?

Best Non-Hormonal Treatments for Hot Flashes Prescription Options Veozah (fezolinetant) - FDA-approved specifically for hot flashes; blocks brain receptors that trigger them. Very effective and relatively new (2023) Brisdelle (paroxetine 7.5mg) - the only FDA-approved SSRI for hot flashes Effexor (venlafaxine) - widely used off-label, well-studied for hot flash relief Over-the-Counter Supplements Remifemin (Black Cohosh) - most studied herbal option with decent evidence Bonafide Relizen - plant pollen extract with good clinical backing and no phytoestrogens Estroven - popular blend containing black cohosh, widely available Lifestyle Tools Embr Wave - wristband that uses temperature therapy to reduce hot flash intensity Chill Factor cooling towels/pillows for nighttime symptoms Key Recommendations Veozah is considered the most effective non-hormonal prescription option currently available Bonafide Relizen is a top OTC choice because it's estrogen-free and clinically tested Talk to your doctor before starting any treatment, especially prescriptions Would you like more detail on any of these options?

Mentioned in position 1 of 8

Read full answer with sources →
PerplexityJun 12, 2026, 11:05 UTC
What actually helps with perimenopause symptoms besides hormones?

Besides hormone therapy, several evidence-based and supportive options can help manage perimenopause symptoms (such as hot flashes, night sweats, mood changes, and sleep disturbances). These include: FDA-Approved Non-Hormonal Medications Paroxetine (7.5 mg low-dose): The only SSRI specifically FDA-approved for treating hot flashes and night sweats in women without mood disorders. Fezolinetant (Veozah): A newer FDA-approved neurokinin-3 (NK3) receptor antagonist that directly targets the body’s temperature regulation system to reduce hot flashes. Other SSRIs/SNRIs (used off-label but supported by studies): Escitalopram (Lexapro) Venlafaxine (Effexor) Citalopram (Celexa) Bupropion (Wellbutrin) – may also help with sexual satisfaction. Other Prescription Medications (Off-Label Use) Gabapentin: An anticonvulsant that can reduce hot flash frequency, especially at night. Oxybutynin: Approved for overactive bladder but shown in trials to reduce hot flashes (30–50% improvement); may be especially helpful if you also have urinary symptoms. Modafinil: Some evidence suggests benefit for sleep and fatigue, though research is limited. Mind-Body & Behavioral Therapies Cognitive Behavioral Therapy (CBT): Strong evidence shows CBT reduces the frequency and severity of hot flashes and improves quality of life. Clinical Hypnosis: Demonstrated to reduce hot flash frequency compared to no treatment. Mindfulness-Based Stress Reduction (MBSR): Growing evidence supports its role in lowering hot flash severity. Acupuncture: May help modulate neurotransmitters and reduce hot flashes and insomnia, though effects on estrogen levels are minimal. Lifestyle & Dietary Adjustments Weight Management: Losing excess weight has been linked to reduced hot flash intensity. Dietary Changes: Soy and phytoestrogens (e.g., flaxseed, soy products): May modestly alleviate hot flashes, though results vary. Omega-3 fatty acids (from fish like salmon, sardines, or plant sources like chia and flax): Support cardiovascular, mood, and cognitive health. Sleep Hygiene: Use of white noise machines, calming bedtime routines, aromatherapy (lavender, eucalyptus), and avoiding screens before bed. “Chillows” or handheld fans can help manage body temperature during hot flashes. Supplements (Limited Evidence) While many supplements are marketed for perimenopause, most lack strong evidence and are not more effective than placebo: Black cohosh: Some studies show modest benefit for hot flashes; safety data is mixed. Evening primrose oil: Limited evidence; may help with breast pain in premenopausal women. Ashwagandha, Rhodiola, Magnesium, Omega-3s: May offer general support for mood, stress, or sleep but are not proven to directly treat hot flashes. Note: According to major health organizations (including Harvard, Mayo Clinic, and the Office on Women’s Health), no herb or supplement has been consistently proven superior to placebo for reducing hot flashes and night sweats. Summary: What Actually Works ✅ Strongly Supported: Low-dose paroxetine or fezolinetant (FDA-approved) Other SSRIs/SNRIs (supported by multiple studies) CBT and clinical hypnosis Gabapentin and oxybutynin (off-label but effective) ⚠️ Mildly or Inconsistently Supported: Soy/phytoestrogens, black cohosh, acupuncture, omega-3s Sleep hygiene tools (fans, chillows, aromatherapy) ❌ Not Evidence-Based: Most supplements marketed for hot flashes (e.g., evening primrose, ashwagandha) unless used for general wellness For personalized care, consult a healthcare provider to evaluate symptom severity, medical history, and eligibility for prescription options.

Mentioned in position 1 of 5

Read full answer with sources →
ClaudeJun 11, 2026, 20:07 UTC
I am 47 with hot flashes and terrible sleep. What are my treatment options?

Managing Hot Flashes & Sleep Issues at 47 You're likely in perimenopause, and there are several good options: Medical Treatments (Most Effective) Hormone Therapy (HRT/MHT) Vivelle-Dot or Climara (estrogen patches) – well-studied, highly effective Bijuva – combined estrogen/progesterone oral pill Talk to your OB/GYN or a menopause specialist (find one at menopause.org) Non-Hormonal Prescriptions Veozah (fezolinetant) – newer FDA-approved drug specifically for hot flashes Brisdelle (paroxetine) – low-dose antidepressant approved for hot flashes Telehealth Options Midi Health – specializes in perimenopause/menopause care Alloy Women's Health – online menopause prescriptions Evernow – similar menopause-focused platform Sleep Support Magnesium Glycinate (brands: Thorne or Pure Encapsulations) – helps sleep quality Oura Ring – tracks sleep to identify patterns Lifestyle Cognitive Behavioral Therapy for Insomnia (CBT-I) via app Sleepio Cooling mattress pads like Eight Sleep ⚕️ Please consult a doctor – especially to determine if HRT is appropriate for you personally.

Mentioned in position 5 of 14

Read full answer with sources →

Public AI visibility history

Daily rank of Veozah on our buyer intent questions, per category. A dash means the engines did not cite Veozah at all that day. This record is permanent.

CategoryJun 11Jun 12Jun 13
Menopause and women's health#26#35#17

TL;DR

Veozah (veozah.com) is a prescription non-hormonal medication approved by the FDA for treating moderate-to-severe vasomotor symptoms, commonly known as hot flashes, associated with menopause. It is manufactured by Astellas Pharma and works as a neurokinin 3 receptor antagonist, a distinct mechanism from both hormone therapy and antidepressant-based alternatives. In WellRank's latest index it ranks 12th in the Menopause and Women's Health category with 8% AI visibility, and all three of its tracked AI mentions carry a positive tone.

Company Overview

Veozah is a branded prescription drug developed and marketed by Astellas Pharma, a global pharmaceutical company headquartered in Tokyo, Japan. The product operates under a traditional pharmaceutical business model, requiring a prescription and dispensed through licensed pharmacies. It received FDA approval in 2023 as the first-in-class fezolinetant-based therapy for menopausal vasomotor symptoms.

Product Features

  • Fezolinetant, a selective neurokinin 3 receptor antagonist targeting the brain pathway responsible for hot flashes
  • Non-hormonal mechanism, making it an option for women who cannot or prefer not to use estrogen-based therapies
  • Once-daily oral tablet formulation
  • Indicated specifically for moderate-to-severe vasomotor symptoms associated with menopause
  • Clinical data published in peer-reviewed literature supporting efficacy and safety, including research indexed at sources like PubMed Central and ScienceDirect

Target Market

Veozah is intended for adult women experiencing moderate-to-severe hot flashes related to menopause, particularly those for whom hormone therapy is contraindicated, such as certain breast cancer survivors or women with a history of hormone-sensitive conditions. It is currently approved and marketed in the United States. Resources from organizations like FORCE (Facing Our Risk of Cancer Empowered) highlight its relevance for high-risk populations avoiding hormones.

Buyer Personas

  • A perimenopausal or postmenopausal woman in her late 40s to 60s who experiences frequent, disruptive hot flashes and is seeking a non-hormonal prescription option.
  • A breast cancer survivor or BRCA gene carrier who has been advised to avoid estrogen-containing therapies and needs an evidence-based alternative, as noted in guidance from womenshealth.gov.
  • A woman who has tried antidepressant-based treatments such as Effexor or Brisdelle and is looking for a mechanism specifically targeting the vasomotor pathway.
  • A patient working with a menopause specialist or OB-GYN who follows clinical guidance and is comfortable with newer, well-studied prescription therapies.

Funding & Performance

Veozah is a commercial product of Astellas Pharma, a publicly traded company listed on the Tokyo Stock Exchange. Specific revenue figures attributable to Veozah alone are not publicly broken out in detail, but Astellas has disclosed the product as a strategic commercial priority in its portfolio communications.

Recent Developments

Since its FDA approval, Veozah has been actively incorporated into clinical discussions about non-hormonal menopause management, including coverage by institutions such as Cleveland Clinic and telehealth platforms like Midi Health. Astellas has continued market education efforts to raise awareness among clinicians and patients about the neurokinin 3 receptor antagonist class. Harvard Health has also included it in guidance on nonhormonal treatments for menopause, reflecting growing mainstream clinical acceptance.

Competitive Landscape

Veozah competes most directly with antidepressant-derived options that are prescribed off-label or indicated for hot flashes, particularly Effexor (venlafaxine) and Brisdelle (paroxetine), the only other FDA-approved non-hormonal option prior to Veozah's entry. It also sits in a broader ecosystem alongside hormone therapies like Vivelle-Dot and wellness-oriented options including Thorne supplements and herbal products like Remifemin. AI engines frequently surface Veozah in the same answers as these alternatives, indicating it is well-positioned as a clinically distinct non-hormonal choice rather than a direct substitute for any single competitor.

Veozah vs the brands AI recommends alongside it

The real competitive set in Menopause and women's health: brands the engines name in the same answers, ranked on the latest day.

BrandRankAI visibility
Veozah logo
VeozahThis brand
#17
8.3%
Brisdelle logo
Brisdelle

2 shared answers

#18
8.3%
Effexor logo
Effexor

2 shared answers

#20
8.3%
Bijuva logo
Bijuva

1 shared answers

#16
8.3%
Bonafide Relizen logo
Bonafide Relizen

1 shared answers

#34
8.3%

Email me when overtakes Veozah

One email the day the ranks flip. Nothing else.

User Sentiment

Within WellRank's tracked AI corpus, all three mentions of Veozah carry a positive tone, with zero neutral or cautious characterizations, suggesting that AI engines consistently frame it as a credible and beneficial treatment option. Public and clinical commentary aligns with this pattern, often emphasizing its novel mechanism and suitability for women who cannot use hormones. No significant negative sentiment signals appear in the sources engines currently cite when mentioning the brand.

Pricing

Pricing for Veozah is not published openly and varies depending on insurance coverage, pharmacy, and any manufacturer savings programs. Astellas has offered a patient savings card program, but specific out-of-pocket costs are not publicly standardized and patients are advised to check directly with their pharmacy or insurer.

Sources cited around Veozah

The sites engines cite in answers mentioning this brand. Win these, win the answer.

Track Veozah weekly

One email a week: rank moves, new competitors, and the answers that changed. No noise.

Work at Veozah? Get your AI Visibility Audit.

See every buyer intent question your customers ask AI, which ones you are losing, who wins them instead, and the exact sources driving those answers. You will finally understand your buyer intent and what Propel would do to win it.